Terry Hackworth, NP
Adult Health · Atlanta, GANPI 1174895643
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $33,668 of the $49,157 with a category attached, or 68.5%. 24 manufacturers reported payments, led by Gilead at 59.9% of the total. Among adult health clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 492 payments — averaging $99.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$29K
- Viiv Healthcare Company$17K
- Merck$815
- EMD Serono, Inc.$420
- Theratechnologies Inc.$387
- AbbVie$316
- plus $1K from 18 others
What the payments were for
- Speaking & faculty fees$33,66868%
- Travel & lodging$5,22711%
- Food & beverage$10,25721%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 150 | $29,470 |
| Viiv Healthcare Company | 170 | $16,509 |
| Merck | 39 | $815 |
| EMD Serono, Inc. | 25 | $420 |
| Theratechnologies Inc. | 22 | $387 |
| AbbVie | 15 | $316 |
| Johnson & Johnson | 17 | $242 |
| Lilly USA, LLC | 12 | $240 |
| Novo Nordisk | 12 | $213 |
| Abbott | 5 | $104 |
| Exact Sciences | 4 | $65 |
| Verity Pharmaceuticals Inc. | 4 | $63 |
| Antares Pharma, Inc. | 3 | $55 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Napo Pharmaceuticals Inc | 2 | $38 |
| Dexcom, Inc. | 2 | $32 |
| CSL Behring | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| GSK | 1 | $19 |
| Halozyme Inc | 1 | $18 |
| AstraZeneca | 1 | $16 |
| Tolmar, Inc. | 1 | $15 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$49,157 in reported general payments places this provider in the 95th percentile of 577 adult health providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 65 | $252,063 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 58 | $225,377 |
| SerostimSomatropin | 11 | $210,319 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 40 | $180,209 |
| DescovyEmtricitabine/Tenofov Alafenam | 59 | $131,293 |
| TivicayDolutegravir Sodium | 55 | $123,448 |
| DovatoDolutegravir Sodium/Lamivudine | 32 | $95,867 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 19 | $72,900 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 15 | $68,363 |
| PrezcobixDarunavir/Cobicistat | 20 | $57,057 |
| IsentressRaltegravir Potassium | 19 | $40,579 |
| Isentress HdRaltegravir Potassium | 12 | $23,315 |
| JanuviaSitagliptin Phosphate | 17 | $21,261 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $7,735 |
| Testosterone | 20 | $4,948 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $29,470 | $456,256143 claims |
| Viiv Healthcare CompanyTriumeq, Tivicay, Dovato | $16,509 | $444,692145 claims |
| EMD Serono, Inc.Serostim | $420 | $210,31911 claims |
| MerckIsentress, Isentress Hd, Januvia, Janumet Xr | $815 | $92,88962 claims |
| Johnson & JohnsonPrezcobix | $242 | $57,05720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 577 adult health providers in Georgia.
Other adult health in Atlanta
- Patricia KeeganAtlanta$224K
- Diane WirthAtlanta$132K
- Barbara WeberAtlanta$74K
- Jenina LagascaAtlanta$17K
- Caleb MagistroAtlanta$17K
- Charise GleasonAtlanta$14K
- Colleen LewisAtlanta$11K
- Dawnelle StedingAtlanta$9K
- Julie WebsterAtlanta$9K
- Gina KellerAtlanta$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.